Xerient Pharma

1 clinical trials · Sponsor

Record	Firm	Date
A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer. (NCT07157033)	Xerient Pharma	2026-01-01

Every clearance here is in the API, with alerts when new ones post.